October 13, 2017Press Releases
AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ — Genprex, Inc., (“Genprex”) a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share. Genprex expects the offering to close on or about November 6, 2017, subject to completion […]